The Children's Hospital Corporation, doing business as Boston Children's Hospital, has been awarded a $258,990 Project Grant under the National Institute of Allergy and Infectious Diseases' (NIAID) Allergy and Infectious Diseases Research program (CFDA 93.855). The grant, titled "Candida Albicans Target of Rapamycin in Oxidative Stress Responses," aims to examine the role of the C. albicans TOR1 kinase and its N-terminal heat repeats in enabling the fungal pathogen to withstand oxidative stress imposed by the host immune system. The research will define the interactions between TOR1 and its N-terminal heat repeats with C. albicans' oxidative stress management systems. The award period is from November 22, 2024, to October 31, 2026.
Generated 3/4/25, 2:34 AM